Opdivo-Yervoy (nivolumab-ipilimumab)

pCPA File Number: 21710

Negotiation Status:

Concluded with an LOI

Indication(s):

Metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations, first-line treatment (in combination with ipilimumab and 2 cycles of platinum-based chemotherapy)

Sponsor/Manufacturer:

Bristol Myers Squibb Canada Inc.

CDA-AMC Project Number:

PC0218-000

pCPA Engagement Letter Issued:

2021-11-01

Negotiation Process Concluded:

2022-01-18